RT期刊论文SR电子T1坚持吸入皮质类固醇和临床结果美泊利单抗在治疗重症哮喘JF欧洲呼吸杂志JO欧洲呼吸ĴFD欧洲呼吸协会SP 1902259 DO 10.1183 / 13993003.02259-2019 VO 55 5 A1 D'安科纳，GráinneA1188bet官网地址卡瓦纳，乔安妮A1罗哈斯，克里斯A1绿色，琳达A1费尔南德斯，马里亚纳A1汤姆逊，路易丝A1达里瓦尔，Jaideep A1 Nanzer，亚历山德拉M. A1杰克逊，戴维·肯特A1，布莱恩D. YR 2020 UL的http：// ERJ。ersjournals.com/content/55/5/1902259.abstract AB介绍吸入糖皮质激素（ICS）实现在大多数哮喘患者的病情控制后，虽然遵守规定的ICS往往较差。患有严重哮喘嗜酸性可能需要具有口服皮质类固醇（OCS）和/或生物剂如美泊利单抗的治疗。It is unknown if ICS adherence changes on, or alters clinical response to, biologic therapy.Methods We examined ICS adherence and clinical outcomes in OCS-dependent severe eosinophilic asthma patients who completed 1 year of mepolizumab therapy. The ICS medicines possession ratio (MPR) was calculated (the number of doses of ICS issued on prescription/expected number) for the year before and the year after biologic initiation. Good adherence was defined as MPR >0.75, intermediate 0.74–0.51 and poor <0.5. We examined outcomes after 12 months of biologic therapy, including OCS reduction and annualised exacerbation rate (AER), stratified by adherence to ICS on mepolizumab.Results Out of 109 patients commencing mepolizumab, 91 who had completed 12 months of treatment were included in the final analysis. While receiving mepolizumab, 68% had good ICS adherence, with 16 (18%) having poor ICS adherence. ICS use within the cohort remained similar before (MPR 0.81±0.32) and during mepolizumab treatment (0.82±0.32; p=0.78). Patients with good adherence had greater reductions in OCS dose (median (interquartile range) OCS reduction 100 (74–100)% versus 60 (27–100)%; p=0.031) and exacerbations (AER change −2.1±3.1 versus 0.3±2.5; p=0.011) than those with poor adherence. Good ICS adherence predicted the likelihood of stopping maintenance OCS (adjusted OR 3.19, 95% CI 1.02–9.94; p=0.045).Conclusion ICS nonadherence is common in severe eosinophilic asthma patients receiving mepolizumab, and is associated with a lesser reduction in OCS requirements and AER.Poor adherence to ICS is common in severe asthma patients receiving mepolizumab, and is associated with increased oral corticosteroid exposure and exacerbation risk http://bit.ly/2v9hdAi